You are not authorized to access this page.

Ferrata Storti Foundation

SHERPA: Unknown

People

  1. Tallman
    Tallman
  2. Levine
    Levine
  3. Zelenetz
    Zelenetz
  4. Mauro
    Mauro
  5. Stein
    Stein
  6. Abdel-Wahab
    Abdel-Wahab
  7. Dogan
    Dogan
  8. Horwitz
    Horwitz
  9. Perales
    Perales
  10. Salles
    Salles

Groups

  1. Department of Medicine (295)
  2. Hematologic Malignancies, Division of (294)
  3. Center for Hematologic Malignancies (270)
  4. Adult Leukemia (107)
  5. Lymphoma (73)
  6. GSK Faculty (70)
  7. Executive Committee, Center for Hematologic Malignancies (60)
  8. Hematologic Malignancies Research (45)
  9. Sloan Kettering Institute Postdocs (43)
  10. Center for Molecular Imaging and Biotechnology (CMIB) (41)
Search Within
Formats
  1. Meeting Abstract (178)
  2. Journal Article (122)
  3. Research Letter (26)
  4. Editorial (17)
  5. Review (12)
  6. Correspondence (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (295)
  2. Hematologic Malignancies, Division of (294)
  3. Center for Hematologic Malignancies (270)
  4. Adult Leukemia (107)
  5. Lymphoma (73)
  6. GSK Faculty (70)

More Groups

People
  1. Carl Landgren (25)
  2. Martin Tallman (25)
  3. Andrew Zelenetz (24)
  4. Ross Levine (24)
  5. Michael Mauro (21)
  6. Anas Younes (16)

More People

Years
  1. 2025 (17)
  2. 2024 (23)
  3. 2023 (17)
  4. 2022 (20)
  5. 2021 (13)
  6. 2020 (18)

More Years

Publications
  1. Haematologica (353)
  2. Haematologica Meeting Reports (4)

Results (357)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The outcome of peripheral T-cell lymphoma patients failing first-line therapy: A report from the prospective, International T-Cell Project
    Journal Article

    Bellei, M.; Foss, F. M.; Shustov, A. R.; Horwitz, S. M.; Marcheselli, L.; Kim, W. S.; Cabrera, M. E.; Dlouhy, I.; Nagler, A.; Advani, R. H.; more...
    Haematologica (2018)

    Fulltext@MSK | Save
  • Present results and future perspectives in optimizing chronic myeloid leukemia therapy
    Journal Article

    Carella, A. M.; Saglio, G.; Mahon, X. F.; Mauro, M. J.
    Haematologica (2018)

    Fulltext@MSK | Save
  • A randomized, open-label, multicenter phase 2 study of daratumumab monotherapy for patients (Pts) with intermediate or high-risk smoldering multiple myeloma (SMM): Centaurus
    Meeting Abstract

    Cavo, M.; Hofmeister, C. C.; Chari, A.; Cohen, Y. C.; Spencer, A.; Voorhees, P.; Estell, J.; Venner, C.; Sandhu, I.; Jenner, M.; more...
    Haematologica (2018)

    Fulltext@MSK | Save
  • Targeting B-cell maturation antigen (BCMA) with GSK2857916 antibody-drug conjugate provides durable responses in patients (Pts) with heavily-pretreated relapsed/refractory multiple myeloma (RRMM): Preliminary results from study BMA117159
    Meeting Abstract

    Popat, R.; Trudel, S.; Lendvai, N.; Voorhees, P.; Reeves, B.; Libby, E.; Richardson, P.; Anderson, L. Jr; Sutherland, H.; Yong, K.; more...
    Haematologica (2018)

    Fulltext@MSK | Save
  • Melflufen therapy for heavily pretreated relapsed refractory multiple myeloma (RRMM) patients refractory to daratumumab and/or pomalidomide: Early efficacy data (Horizon)
    Meeting Abstract

    Mateos, M. V.; Oriol Rocafiguera, A.; Rodríguez-Otero, P.; Bladé, J.; Larocca, A.; Moreb, S. J.; Cavo, M.; Mazumder, A.; Alegre, A.; Hassoun, H.; more...
    Haematologica (2018)

    Fulltext@MSK | Save
  • Safety and efficacy of plerixafor dose escalation for the mobilization of CD34(+) hematopoietic progenitor cells in patients with sickle cell disease: Interim results
    Journal Article

    Boulad, F.; Shore, T.; van Besien, K.; Minniti, C.; Barbu-Stevanovic, M.; Wiener Fedus, S.; Perna, F.; Greenberg, J.; Guarneri, D.; Nandi, V.; more...
    Haematologica (2018)

    Fulltext@MSK | Save
  • Single-agent dabrafenib for BRAF(V600E)-mutated histiocytosis
    Journal Article

    Bhatia, A.; Ulaner, G.; Rampal, R.; Hyman, D. M.; Abdel-Wahab, O.; Durham, B. H.; Dogan, A.; Ozkaya, N.; Lacouture, M. E.; Hajdenberg, J.; more...
    Haematologica (2018)

    Fulltext@MSK | Save
  • Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms
    Journal Article

    Hobbs, G. S.; Hanasoge Somasundara, A. V.; Kleppe, M.; Litvin, R.; Arcila, M.; Ahn, J.; McKenney, A. S.; Knapp, K.; Ptashkin, R.; Weinstein, H.; more...
    Haematologica (2018)

    Fulltext@MSK | Save
  • Patrones de cambio de los inhibidores de la tirosina cinasa BCR-ABL1 en pacientes con LMC en fase crónica en la práctica clínica rutinaria estudio simplicity
    Meeting Abstract

    Encinas, M. P.; Goldberg, S. L.; Michallet, M.; Hehlmann, R.; Zyczynski, T.; Foreman, A.; Calimlim, B.; Paquette, R.; Simonsson, B.; Gambacorti Passerini, C.; more...
    Haematologica (2017)

    Fulltext@MSK | Save
  • Bosutinib (BOS) Vs Imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE Trial
    Meeting Abstract

    Gambacorti-Passerini, C.; Deininger, M.; Mauro, M. J.; Chuah, C.; Kim, D. W.; Reilly, L.; Jeynes-Ellis, A.; Leip, E.; Bardy-Bouxin, N.; Hochhaus, A.; more...
    Haematologica (2017)

    Fulltext@MSK | Save

    • Ferrata Storti Foundation – authorized name for: